EVM
RIGL icon

Eaton Vance Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Eaton Vance Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-60
Closed -$2K – 2510
2021
Q4 		$2K Hold
60
– – ﹤0.01% 2743
2021
Q3 		$0 Hold
60
– – ﹤0.01% 2550
2021
Q2 		$3K Buy
+60
New +$2.27K ﹤0.01% 2686

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eaton Vance Management's RIGL Position: Q1 2022 in Review

Eaton Vance Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 60 shares — an estimated $2K sold.

Eaton Vance Management first reported a position in RIGL in Q2 2021 and held it in 3 quarters. The position peaked at $3K in Q2 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

  • Eaton Vance Management reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 60 Rigel Pharmaceuticals shares in Q1 2022, an estimated $2K.
  • Eaton Vance Management first reported a position in Rigel Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Rigel Pharmaceuticals position peaked at $3K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.